- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4630
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase |
|---|---|
| Other ADC Cytotoxin Products | SN-38 Triptolide (+)-Bicuculline Rutin Artemisinin Pinocembrin BHQ Harmine hydrochloride Psoralen Lappaconite HBr |
|
In vitro |
DMSO
: 46 mg/mL
(199.41 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 230.67 | Formula | C8H7ClN2O2S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 364-98-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Sch-6783, SRG-95213 | Smiles | CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl | ||
| Targets/IC50/Ki |
KATP channels
|
|---|---|
| In vitro |
Diazoxide inhibits microglial inflammatory activity. This compound treatment partially inhibits the inflammatory pattern induced by LPS/IFN-γ in microglial cells, inducing a decrease in NO production that could be because of the decreased expression of iNOS detected. It has no effect on microglial phagocytosis.
|
| In vivo |
Diazoxide is beneficial on the improvement in cognitive tasks, reduction of anxiety, decrease in the accumulation of amyloid-beta oligomers and hyperphosphorylation of tau proteins. This compound may also exerts neuroprotective effects independently of K+ channel activation by decreasing neuronal excitability and activation of N-methyl-D-aspartate (NMDA) receptors or by increasing currents trough
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This chemical-treated animals show a decrease in disease severity a few days after the first clinical signs are observed, corresponding to the acute inflammatory phase of the disease. Daily oral administration of this compound in EAE mice during the effector phase of the disease reduces the severity of the clinical signs without any apparent adverse effect. It decreases demyelination and axonal loss, reduces tissue damage, inhibits microglial/macrophage and astrocytic activation
and preserves neuron integrity. No effects are observed on the number of B and T lymphocytes infiltrating the spinal cord.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03941236 | Active not recruiting | Congenital Hyperinsulinism |
Zealand Pharma |
May 1 2019 | Phase 3 |
| NCT00901823 | Withdrawn | Hypertriglyceridemia |
Essentialis Inc. |
March 2011 | Phase 1 |
| NCT00696475 | Completed | Hypertriglyceridemia |
Essentialis Inc.|Medpace Inc. |
June 2008 | Phase 2 |
| NCT00688857 | Completed | Hypertriglyceridemia |
Essentialis Inc.|Cetero Research San Antonio |
May 2008 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.